Bactrim Drug Rash Presentation
The typical Bactrim (trimethoprim-sulfamethoxazole) rash presents as a delayed-onset maculopapular exanthem (generalized pruritic rash) appearing 4-11 days after drug initiation in first-time users, or within 1 day in previously exposed patients.
Classic Cutaneous Presentations
The most common presentation is a generalized, pruritic maculopapular rash occurring in approximately 76.9% of cases 1. This is a delayed hypersensitivity reaction characterized by:
- Generalized sunburn-like erythema without scale 2
- Pruritic (itchy) quality
- Onset timing: 4-11 days after first exposure, or ≤1 day with prior exposure 2
- May be accompanied by mild facial and acral edema 2
The second most common presentation is urticaria/angioedema (15.4% of cases) 1, representing an immediate-type reaction.
Associated Systemic Features
Beyond the rash itself, watch for these accompanying findings that signal more serious reactions:
Early warning signs 3:
- Conjunctivitis (very common in hypersensitivity reactions) 2
- Fever (present in 6 of 7 patients in one series) 2
- Pharyngitis
- Arthralgia
Laboratory abnormalities 2:
- Lymphopenia (universal finding in hypersensitivity reactions)
- Eosinophilia (particularly in DRESS syndrome) 4
- Elevated liver enzymes
- Thrombocytopenia
Hemodynamic changes 2:
- Hypotension (present in all 7 patients in one series)
- Tachycardia (universal finding)
Severe Cutaneous Adverse Reactions (SCARs)
The FDA explicitly warns that skin rash may progress to life-threatening conditions 3. These include:
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Drug reaction with eosinophilia and systemic symptoms (DRESS) 4
- Acute generalized exanthematous pustulosis (AGEP)
- Acute febrile neutrophilic dermatosis (AFND)
Critical management principle: The FDA mandates discontinuing Bactrim at the first appearance of skin rash 3, as continuing therapy risks progression to these potentially fatal reactions.
Special Presentations
Fixed drug eruption: Presents as oval-circular erythematous patches with itching and burning pain, can occur in anogenital areas 5. Develops rapidly (within 15 minutes to hours) after drug exposure and leaves post-inflammatory hyperpigmentation.
SCoRCH syndrome (Sudden Conjunctivitis, lymphopenia, and Rash Combined with Hemodynamic changes): A newly described hypersensitivity pattern specific to TMP-SMX characterized by the triad of generalized sunburn-like erythema, conjunctivitis, and hemodynamic instability with lymphopenia 2. Resolution typically occurs within 48-96 hours.
High-Risk Populations
AIDS patients have markedly increased incidence of cutaneous reactions compared to non-AIDS patients 3. The most common reaction remains generalized pruritic maculopapular rash 1.
Risk factors for severe reactions 6:
- Slow acetylator phenotype
- Glutathione deficiency
- History of previous adverse cutaneous reactions
- Elderly patients (increased thrombocytopenia risk with concurrent diuretics) 3
Timeline Considerations
For rechallenge evaluation 7: The 2022 practice parameter distinguishes reactions by timing:
- Immediate reactions (onset <1 hour): typically urticaria, angioedema
- Accelerated reactions (onset >1 hour to 36 hours)
- Delayed reactions (onset >36 hours): typically maculopapular exanthem
Reactions occurring >5 years ago have lower recurrence risk and may be appropriate for single-step rechallenge in non-severe cases 7.
Critical Pitfall
Never continue Bactrim through a rash. The FDA warning is unequivocal: discontinue at first appearance of skin rash 3. The notion that "treating through" mild rashes is acceptable can lead to Stevens-Johnson syndrome or toxic epidermal necrolysis 6, both potentially lethal.